Post Marketing Surveillance Study of Actimmune in Patients With Severe, Malignant Osteopetrosis
Completed
Conditions studied: Osteopetrosis
In brief
The purpose of this study is to establish a registry of all children with severe, malignant osteopetrosis who are treated with Actimmune (IFN-g 1b or Interferon gamma-1b) to monitor the effects of IFN-g 1b on preventing progression of this disease and to follow the safety of patients receiving it on a long-term basis. In addition, evaluation of the possible effect of Actimmune therapy on the humoral response to normal childhood vaccinations in this same patient population will be examined.Interferon gamma is a substance that the body makes naturally.
Key facts
- Study ID
- NCT00043329
- Run by
- InterMune
- People needed
- 6
- Starts
- 2002-01-01
- Expected to finish
- 2005-09-01
- Last updated by the study team
- 2007-11-01
Who can join
Age: any. Sex: any. Healthy volunteers: not accepted.
Where it is running
- InterMune, Inc. — Brisbane, California, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.